Therapeutic inhibition with the E-selectin inhibitor uproleselan (GMI-1687) has shown impressive preclinical efficacy, synergizing with cytarabine to double survival duration in AML mouse models (Barbier et al., 2020), and subsequently reported encouraging results including an impressive CR rate of 41% in a phase 1/2 clinical trial of relapsed/refractory AML (DeAngelo et al., 2018). The gene discussed is SELE; the disease is acute myeloid leukemia.